Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment

doi:10.5306/wjco.v16.i11.108667

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

(34)

(0)

(8)

(1750)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Nov 24, 2025; 16(11): 108667
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.108667

Full Size Figure Download Figure

Figure 6 Considerable disadvantages of chimeric antigen receptor T cell therapy. A: Key challenges that can probabilistically reduce chimeric antigen receptor (CAR)-T efficacy; B: Major toxicities associated with CAR-T treatment. CAR: Chimeric antigen receptor; TAA: Tumor-associated antigen; Treg: Regulatory T cell; CAF: Cancer associated fibroblast.

Citation: Arjumand S, Raj A, Prattay KMR, Omer HBM, Azam F. Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment. World J Clin Oncol 2025; 16(11): 108667
URL: https://www.wjgnet.com/2218-4333/full/v16/i11/108667.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i11.108667

Arjumand S, Raj A, Prattay KMR, Omer HBM, Azam F. Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment. World J Clin Oncol 2025; 16(11): 108667 [PMID: 41355907 DOI: 10.5306/wjco.v16.i11.108667]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.